Novo Nordisk shortage of Ozempic and Wegovy ends, threatening compounders

What's new in pharma

February 21, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Novo Nordisk shortage of Ozempic and Wegovy ends, threatening compounders FDA declares end to Novo Nordisk's semaglutide shortage, a threat to online companies selling compounded versions of Ozempic, Wegovy. By Elaine Chen STAT+ | Maryland lawmakers vote to expand powers of the state's prescription drug affordability board The House of Delegates voted overwhelmingly to allow a state board to extend its mandate for lowering prescription drug costs to all residents. By Ed Silverman STAT+ | Bluebird Bio sells itself to Carlyle, SK Capital for less than $30 million The company's sale marks a quiet end for a once-high-flying biotech that was set to run out of cash virtually any day By Jason Mast Adobe National Academies is altering pending reports to appease Trump administration, some members say Words such as "health equity" are being replacing with vaguer terms, and 100 members sent a letter of protest to NASEM leaders. By Usha Lee McFarling STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman Federal judge extends restraining order on Trump administration's cap on NIH indirect costs The temporary restraining order was set to expire on Monday, but has been extended until the judge can make a final decision on an injunction By Anil Oza

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser